Anti-Malarial Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Anti Malarial Drugs Classification and the market is segmented by Drug Class (Aryl amino alcohol compounds, Antifolate compounds, Artemisinin compounds, and Other Drug Types), Malaria Type (Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malarie, Plasmodium Ovale) Mechanism of Action (Treatment for Malaria, Prevention from Malaria)and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Anti-Malarial Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Anti Malarial Drugs Industry Overview

The majority of the anti-malarial drug is being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. These global players are mostly based in developed countries like the United States, the United Kingdom, France, Germany, and Japan. Asia-pacific is also witnessing the emergence of some small players which has helped the market growth and increased its competitiveness. Some of the major players in the market include, Cipla, GlaxoSmithKline PLC, Novartis AG, Strides Pharma Science Limited, Glenmark Pharmaceuticals, Bayer AG, Alvizia Healthcare, among others. 

Anti Malarial Drugs Market Leaders

  1. Cipla

  2. Novartis AG

  3. Strides Pharma Science Limited

  4. Glenmark Pharmaceuticals

  5. GlaxoSmithKline PLC

  6. *Disclaimer: Major Players sorted in no particular order
Anti-Malarial Drugs Market Concentration

Anti Malarial Drugs Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?